Vancouver, British Columbia — January 19, 2026 — Leads & Copy — DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) announced encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRx™ Red Eye diagnostic platform.
The TeaRx™ Red Eye diagnostic platform is a rapid, multi-biomarker, point-of-care diagnostic device designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis. These three conditions account for hundreds of millions of clinic visits worldwide each year.
The Israeli clinical program was initiated in October 2023 and includes sites such as two Leumit Health Services clinics in Tel-Aviv and Jerusalem, one Clalit Health Services clinic in Jerusalem, Kaplan Medical Center in Rehovot, Shaare Zedek Medical Center in Jerusalem, and Soroka Medical Center in Beer-Sheva. The study enrolls patients presenting with suspected infectious or allergic red eye and involves collection of tear fluid samples by conjunctival swabbing.
Each sample is independently characterized using established laboratory reference methods, including qPCR testing for ocular Herpes (HSV-1 and HSV-2), qPCR and the QuickVue® Adenovirus test (QuidelOrtho), for Adenovirus, and quantitative ELISA for total tear IgE (biomarker for ocular allergy), and is tested in parallel using the TeaRx™ Red Eye assay.
To date, 130 subjects have been recruited into this study. Among these, 66 samples have been evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE, meeting protocol criteria for eligibility. Based on these eligible samples, TeaRx™ Red Eye has demonstrated positive and negative agreement rates of 92% and 100% for Adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, respectively, when compared to the independent reference methods.
The interim results indicate that TeaRx™ Red Eye reliably identifies viral causes of red eye, supporting clearer point-of-care decisions and reducing unnecessary treatments.
Dr. Shimon Gross, CEO of DiagnosTear, said the interim results represent a major step forward in the validation of TeaRx™ Red Eye. He added that achieving very high agreement for adenovirus and HSV in real-world, multi-center clinical settings supports their vision of delivering reliable, actionable diagnostics directly at the point of care, and that the IgE data is also encouraging and continues to improve as enrollment expands.
The Israeli study is expected to be completed by the second quarter of 2026. DiagnosTear has also initiated complementary clinical programs in India, focused on HSV, and in France, focused on tear IgE for allergic conjunctivitis, both of which are also expected to be completed by the second quarter of 2026.
Dr. Gross added that by combining data from Israel, India, and France, the company is building one of the most comprehensive clinical and analytical datasets ever assembled for a red-eye diagnostic platform. He said their goal is to give primary care physicians, as well as eye-care providers a fast and objective tool that improves how red-eye patients are diagnosed and treated.
Pending final validations, DiagnosTear plans to advance TeaRx™ Red Eye toward regulatory submissions and commercial launch in key global markets including the US and the EU.
DiagnosTear Technologies Inc. develops multi-parametric tests that provide clinically actionable insights based on tear-fluid analysis. DiagnosTear’s mission is to transform ophthalmic care with accessible diagnostics that support precise, data-driven decision making.
Contact:
Dr. Shimon Gross
Chief Executive Officer
DiagnosTear Technologies Inc.
+972-52-3408550
shimon@diagnostear.com
Source: DiagnosTear Technologies Inc.
